ORMAT TECHNOLOGIES, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ORA in the last 30 days.
See all $ORA insider activity →Ormat Technologies (ORA) received up to $35 million in funding from the U.S. Department of Energy. The stock closed at $93.07, with a 1-day return of 1.95%, but a 30-day return of -11.74% and a year-to-date return of -18.17%. Analysts estimate a fair value of $127.67, suggesting a 27% undervaluation. However, the P/E ratio of 45.2x raises concerns about overvaluation.
Analysts this week focused on valuation discipline, trimming winners and cutting stalled growth stories. Key moves: Wells Fargo downgraded FS KKR (FSK) to Underweight with a $10 target, citing credit risks. Stifel upgraded STAAR Surgical (STAA) to Buy, raising its target to $31. Deutsche Bank downgraded Commerzbank (CBKG) to Hold. Citizens downgraded Foghorn Therapeutics (FHTX) after a drug trial failure. UBS downgraded Gurit Holding (GURN) to Neutral.
Ormat Technologies received up to $35M in DOE funding for geothermal projects. The funding supports its Enhanced Geothermal Systems and carbonate reservoir work, aligning with its core capabilities. Analysts project $1.3B revenue and $224.6M earnings by 2029, with a 37% potential upside. Key risks include high capital expenditure, net debt, and weak interest coverage.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning ORA (ORMAT TECHNOLOGIES, INC.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.
Recent ORA coverage spans financial news, market movers and earnings.
Funding announcement may lift ORA as investors price in new growth potential.
Neutral rating may limit upside.
Ormat Technologies received up to $35M in DOE funding for geothermal projects. The funding supports its Enhanced Geothermal Systems and carbonate reservoir work, aligning with its core capabilities. Analysts project $1.3B revenue and $224.6M earnings by 2029, with a 37% potential upside. Key risks include high capital expenditure, net debt, and weak interest coverage.
Target cut and downgrade increase downside risk.
The downgrade signals limited earnings upside and puts downward pressure on the stock.
AlphAI scores every news story that mentions ORA with an AI model for sentiment and relevance, and aggregates insider trades from ORMAT TECHNOLOGIES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Ormat Technologies (ORA) received up to $35 million in funding from the U.S. Department of Energy. The stock closed at $93.07, with a 1-day return of 1.95%, but a 30-day return of -11.74% and a year-to-date return of -18.17%. Analysts estimate a fair value of $127.67, suggesting a 27% undervaluation. However, the P/E ratio of 45.2x raises concerns about overvaluation.
2 min readAnalysts this week focused on valuation discipline, trimming winners and cutting stalled growth stories. Key moves: Wells Fargo downgraded FS KKR (FSK) to Underweight with a $10 target, citing credit risks. Stifel upgraded STAAR Surgical (STAA) to Buy, raising its target to $31. Deutsche Bank downgraded Commerzbank (CBKG) to Hold. Citizens downgraded Foghorn Therapeutics (FHTX) after a drug trial failure. UBS downgraded Gurit Holding (GURN) to Neutral.
2 min readOrmat Technologies received up to $35M in DOE funding for geothermal projects. The funding supports its Enhanced Geothermal Systems and carbonate reservoir work, aligning with its core capabilities. Analysts project $1.3B revenue and $224.6M earnings by 2029, with a 37% potential upside. Key risks include high capital expenditure, net debt, and weak interest coverage.
2 min readAnalysts downgraded several stocks: BTIG cut Liquidia (LQDA) to Neutral, BMO reduced Sigma Lithium (SGML) to Market Perform with a $10 target, Wells Fargo downgraded ExxonMobil (XOM) to Equal-Weight with a $182 target, UBS lowered Ormat (ORA) to Neutral with a $100 target, and JP Morgan changed Ethos (LIFE) to Neutral. Prices as of Wednesday's close: LQDA $30.26, SGML $9.40, XOM $162.75, ORA $91.49, LIFE $33.57.
2 min readOrmat Technologies (NYSE:ORA) shares dropped 3.4% after UBS downgraded the stock to Neutral from Buy, cutting its price target to $100 from $157. The downgrade followed Ormat's reduced 2028 adjusted EBITDA guidance and lower growth forecasts. UBS cited limited earnings upside through 2028 and valuation multiples in line with peers.
1 min readWall Street analysts issued updates on various companies. BP (NYSE: BP) was upgraded to Overweight with a $71 target, Dollar Tree (NASDAQ: DLTR) to Buy with a $140 target, and Occidental Petroleum (NYSE: OXY) to Buy with a $69 target. Exxon Mobil (NYSE: XOM) was downgraded to Equal Weight with an $182 target. Other notable initiations and changes include Lennar (NYSE: LEN), Rocket Lab (NASDAQ: RKLB), Teva Pharmaceuticals (NASDAQ: TEVA), and more.
3 min readOrmat Technologies (NYSE: ORA) received up to $35m in US DOE funding for geothermal projects. $25m for EGS project in Nevada, $9.7m for Utah project. Awards pending negotiations. Market cap $5.8B. Stock up 1.2% on news, down 35% from 2026 peak.
1 min readOrmat Technologies (ORA) reported Q2 revenue growth of 10.6% YoY to $258.8M, with energy-storage revenue up 195% YoY. Google (GOOG) agreed to use Ormat's geothermal energy for AI data centers. Ormat is developing enhanced geothermal systems (EGS) with Pentagon interest. The company expects $1.15B-$1.2B revenue in 2026, with a low EV/EBITDA ratio of 16.6x.
3 min readPresident Capital initiated coverage of Ormat Technologies with a Buy rating and a $129 price target. The stock has risen 2.68% in 5 days and 0.70% year-to-date, following a recent upgrade from Bernstein to Market Perform with a $112 target.
1 min readOrmat Technologies (ORA) reported Q2 2026 earnings and revenue above expectations, raising full-year guidance. Shares rose 7.6% in a month, though down 24.7% in three months. Analysts' average price target is $135.45, with a range of $122.0 to $152.0. The company faces risks from Chinese battery reliance and high capital spending.
2 min read
